.Attribute Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a median follow-up of 11 months, people with metastatic gastrointestinal tumors who received biomarker-matched therapies based on flowing lump DNA profiling showed a greater medical perk than those obtaining incomparable treatment.